Edition 2 / June 2021
Dr. Stephen Houldsworth,
VP, Global Head of Platform Management & Marketing
Since 2021 marks the 15 Year Anniversary of CordenPharma, we will begin looking back on our journey since being founded in 2006 with the acquisition of CordenPharma Chenôve, near Dijon France, in 2007.
This first API cornerstone in our family of facilities helped form the foundation of our integrated supply network of facilities across Europe & the US. Thus began the journey of transforming former Large Pharma & Biotech assets into a ONE PARTNER CDMO.
In this 15 Year Anniversary video, Managing Director Yves Michon talks about the initial transition of going from a Pharma asset to a global CDMO, and what was required to shift the mentality of his team. He also highlights new cutting-edge technology like their Centre of Excellence for Flow Chemistry and continuous manufacturing plant for clinical supplies.
He elaborates as well on the success of CordenPharma Chenôve as one of four CordenPharma facilities to contribute towards the expanded supply agreement with Moderna for the production of lipids for their COVID-19 mRNA vaccine.
The whole CordenPharma organization was honored by the visit of EU Commissioner for Vaccines Strategy & Steering Thierry Breton, whose arrival on Easter Sunday (April 4, 2021) acknowledged and encouraged workers as they continued their around-the-clock production.
We look forward to continuing our reflection of CordenPharma’s 15 Year Anniversary milestone acquisitions over the coming months.
Located in the Burgundy region of Central-Eastern France, CordenPharma Chenôve is a cGMP manufacturer of advanced pharmaceutical intermediates and APIs, specializing in synthetic route design and development of small molecule candidates.
Stay up to date with the latest thought leadership articles and news from CordenPharma.